The technology for hybridizing archived tissue specimens and the use of laser-capture microdissection for selecting cell populations for RNA extraction have increased over the past few years. Both these methods contribute to RNA degradation. Therefore, quality assessments of RNA hybridized to microarrays are becoming increasingly more important. Existing methods for estimating the quality of RNA hybridized to a GeneChip, from resulting microarray data, suffer from subjectivity and lack of estimates of variability. In this article, a method for assessing RNA quality for a hybridized array which overcomes these drawbacks is proposed. The effectiveness of the proposed method is demonstrated by the application of the method to two microarray data sets for which external verification of RNA quality is known.
INTRODUCTION
Microarrays are high-throughput devices that are able to assess the abundance of thousands of RNA transcripts in one sample. Although in oncology traditional histopathological features (such as tumor size, appearance, and evidence of local spread) continue to be used as prognostic indicators, microarrays are emerging as a potential tool for identifying genes and gene expression patterns predictive of responses (Bhattacherjee et al., 2001; Chang et al., 2003; Golub et al., 1999) . The hope is that with improved prognostic features from genome-wide surveys such as microarrays and translational research, clinicians will be able to better match optimal cancer treatments to specific patients (Ramaswamy, 2004) .
Due to tissue procurement limitations, the expense of microarray gene expression research, and the necessity of studying biological rather than technical replicates, investigators typically extract RNA from a given tumor and hybridize the RNA to one microarray. Various steps involved in procuring tumor samples (e.g. time from extripation to freezing) and extracting RNA from a given tumor are known to lead to degradation of the sample. Recently, we reported a set of preanalytical quality control parameters that allow assessing the integrity of a total RNA sample, before hybridizing it to a GeneChip array (Dumur et al., 2004) . Since conclusions drawn from statistical analyses of microarray data from degraded RNA samples could be misleading, verification of RNA quality is an important aspect of the microarray experimental process (Auer et al., 2003; Dumur et al., 2004) . Due to the labile nature of RNA, quality assessments will become increasingly more important as both the technology for hybridizing archived tissue specimens and the use of laser-capture microdissection for selecting cell populations for RNA extraction increase.
To understand the effect RNA degradation has on gene expression, consider the process by which RNA for hybridization is obtained. The process of reverse transcription begins with reverse transcriptase binding to a primer oligonucleotide annealing at the 3 end of a gene and processing toward the 5 end. However, transcription generally does not continue to completion because it typically drops off before reaching the 5 end. Therefore, microarrays such as Affymetrix GeneChips are usually manufactured with features whose primary purpose is to assess the efficiency of transcription. For instance, the Affymetrix GeneChips include probe sets that interrogate both the 3 and 5 ends of selected transcripts. Once a sample has been hybridized to a GeneChip, the ratios of the 3 to 5 signal intensities are calculated for each internal control gene, as a quality assessment demonstrating the degree to which the gene was transcribed (Affymetrix, 2001) . A large 3 :5 ratio is considered to be indicative of a problem during RNA extraction, where the starting RNA was not of full length (degraded); during cDNA synthesis reaction where mRNA may not have been fully converted to cDNA; and/or during the in vitro transcription (IVT)/biotin labeling reaction where the cDNA was not properly converted to biotinylated cRNA.
In Section 2, the two data sets that will be used for illustrative purposes are introduced. For each chip in these data sets, external indicators of RNA quality are known. Therefore, the sensitivity and specificity of the existing quality assessment methods as well as the proposed method can be examined. In Section 3, existing methods for assessing the RNA quality are presented. The results from applying the existing methods to the data sets are presented in Section 4, where the limitations of these methods are also discussed. In Section 5, an alternative method for assessing RNA quality is proposed. The proposed method provides a single summary estimate of quality with an associated confidence interval. Section 6 presents the results after applying the proposed method and the implications of this research are discussed in Section 7.
2. DATA
Ovarian tumor samples
Previously published data (Dumur et al., 2004) consisting of five pairs of HG-U133A GeneChips were hybridized as follows: first, total RNA was isolated from multiple 10-µm frozen sections from five snap-frozen ovarian tumor samples using TRIZOL reagent. Afterward, for each tumor, similar-sized aliquots of total RNA were processed in two different ways: with and without a subsequent cleanup process using RNeasy reagents. The RNeasy cleanup should lead to good-quality RNA (GeneChips Ovarian1 G, Ovarian2 G, Ovarian3 G, Ovarian4 G, and Ovarian5 G), whereas lack of the cleanup step should yield inhibited or poor-quality RNA (GeneChips Ovarian1 I, Ovarian2 I, Ovarian3 I, Ovarian4 I, and Ovarian5 I). Details confirming the RNA quality, such as absorbency ratios, 28S/18S ratios, and length of cDNA and cRNA synthesis products, are reported elsewhere (Dumur et al., 2004) . The samples were obtained and processed according to Virginia Commonwealth University's Institutional Review Board approved protocol.
Renal cell carcinoma samples
Previously published data collected to assess the impact of RNA degradation on microarray gene expression in renal cell carcinoma samples (Schoor et al., 2003) will also be used for illustrative purposes. This published study was conducted at the University of Tübingen and included nine Affymetrix GeneChips (4 HG-U133A; 5 HG-Focus). The goal of this study was to examine the effects of a two-round IVT protocol on 20 ng of partially degraded RNA on gene expression values in comparison to expression values obtained when high-quality RNA is hybridized. The RNA extraction and chemical degradation procedures have been described elsewhere (Schoor et al., 2003) . The nine samples from this study have been labeled as follows:
• the first letter indicates cell type, with 'N' indicating normal cells and 'T' indicating tumor cells;
• the second letter reflects the level of degradation, ranging from 'A' indicating freshly isolated RNA (i.e. no degradation) to 'D' indicating the highest amount of degradation; and
• for hybridized GeneChips, the third letter reflects the GeneChip used, with 'U' indicating HG-U133A and 'F' indicating HG-Focus.
An additional factor included in this study was the processing method of the initial total RNA. The standard Affymetrix protocol on 15 µg RNA was used for the NA-U and TA-U GeneChips; a small sample protocol consisting of two rounds of IVT on 20 ng of RNA was used for the NA-F, TA-F1, TA-F2, NB-F, TB-F, ND-U, and TD-U GeneChips. Extent of degradation was confirmed for all samples by electropherogram by reporting the 28S/18S ratios using the RNA 6000 Pico LabChip kit with a Model 2100 Bioanalyzer (Aligent Technologies, Waldbronn, Germany) (Schoor et al., 2003) . The local ethical committee at the University of Tübingen approved the study and informed consent was obtained.
EXISTING METHODS FOR ASSESSING THE QUALITY OF A HYBRIDIZED CHIP

The 3 :5 ratio
Once a sample has been hybridized to a GeneChip, the degree to which the gene was transcribed can be assessed by the ratio of the 3 to 5 signal intensities for each internal control gene (Affymetrix, 2001) . It has been suggested in the literature that this ratio should be examined for assessing the quality of the sample hybridized to the given array. The GeneChip Operating Software (GCOS) estimates the 3 :5 ratio after the perfect match (PM) and mismatch (MM) probes have been summarized into a probe set expression measure (Affymetrix, 2003; Hubbell et al., 2002) . The manufacturer suggests that ratios greater than 3 may indicate degraded RNA or insufficient transcription (Affymetrix, 2003) .
Various alternative methods for summarizing probe-level data into probe set summaries have been reported in the literature (Irizarry et al., 2003a,b; Lemon et al., 2002; Li and Wong, 2001b) . Unfortunately, inherent to all probe set expression summary methods applied to Affymetrix GeneChip data is that many genes are represented by only one probe set on a GeneChip. Relying on summarized probe set data for the assessment of the 3 :5 ratios does not allow for estimates of uncertainty due to the lack of replicates of 3 and 5 probe sets on a chip.
RNA degradation plots
A method referred to as 'RNA digestion plots' for assessing RNA degradation is available in the Bioconductor affy package (Gautier et al., 2004) . Since the at1, at2, . . . , at11 probes are arranged in order of their interrogation position of the gene (with at1 being closer to the 5 end and at11 being closer to the 3 end), the RNA digestion plot, which plots the overall average expression by probe interrogation position (average of at1s, average of at2s, etc.), can be used in assessing sample degradation as follows. If transcription dropped off before reaching the 5 end, this plot would show an increasing positive slope. Additionally, the magnitude of the slope and its associated p-value for testing whether the slope is significantly greater than zero can be examined.
APPLICATION OF THE EXISTING METHODS
The two methods described in Section 3 were applied to the data sets introduced in Section 2. The results are presented in this section.
The 3 :5 ratio
The *.DAT files were analyzed using GCOS in order to produce the Microarray Suite version 5.0 (MAS 5.0) expression summaries, the associated *.CEL files, and the reports reflecting the 3 to 5 ratios for the human control probe sets. It has been suggested that when analyzing GeneChip data, more than one expression summary method should be examined (The Tumor Best Practices Working Group, 2004) . This recommendation is due to the fact that no single probe set expression summary method has emerged as the 'best' method and due to the influence that expression summary methods have on downstream analyses. Therefore, the *.CEL files were subsequently used to obtain the robust multiarray average (RMA) (Irizarry et al., 2003a) and GC-RMA expression summaries (Wu et al., 2004) using the R programming environment (Ihake and Gentleman, 1996) and the Bioconductor affy (Gautier et al., 2004) and gcrma libraries. Probe-level data were also summarized using the PM-only model-based expression index (MBEI) using the dChip version 1.3 software (Li and Wong, 2003) .
The 3 to 5 ratios calculated after summarizing probe-level data using the MAS 5.0, RMA, GC-RMA, and the PM-only MBEI algorithms appear in Table 1 . Notice that the interpretation of degradation heavily depends on which expression summary method is used. For example, RMA expression summaries of all 3 to 5 ratios are near 1, leading one to conclude adequate sample quality. This is irrespective of whether degradation is known to be truly present or absent in the sample. For various GeneChips, the MAS 5.0, GC-RMA, and MBEI summaries lead one to draw a different conclusion regarding sample quality depending upon whether the GAPDH or β-actin ratios are compared to the recommended threshold of 3. These discrepancies between the 3 and 5 ratios for different transcripts within the same GeneChip are ambiguous, thereby presenting a difficulty in drawing a final conclusion regarding sample quality. The observed differences in the 3 to 5 ratios among the different probe set expression summary methods (MAS, RMA, GC-RMA, and MBEI) are analogous to the findings that class comparisons performed using different expression summary methods will lead to different lists of genes identified as differentially expressed (The Tumor Best Practices Working Group, 2004) . In fact, due to the lack of replicates of 3 :5 probe sets, it is not possible to provide an estimate of the uncertainty (variance) for the 3 :5 ratio when probe set expression summaries are used in their estimation. Moreover, the practice of comparing the 3 :5 ratio to a predetermined threshold is analogous to the use of fold-change thresholds for identifying differentially expressed genes, which has been demonstrated to be clearly inferior to statistical approaches which take variability into consideration (Dudoit et al., 2002; Zhang et al., 2002) . Establishing a viable threshold for quality determination is therefore problematic particularly when different probe set expression summary methods are available for use. Therefore, a method for assessing the 3 to 5 ratio that is independent of an expression summary method is desirable.
RNA digestion plots
The RNA digestion plots for the HG-U133A GeneChips appear in Figure 1 (A) and the RNA digestion plot for the HG-Focus GeneChips appear in Figure 1 (B). For the renal cell samples, the linearity observed for the GeneChips to which freshly isolated RNA was hybridized (NA-U and TA-U, Figure 1A ; NA-F, TA-F1, and TA-F2, Figure 1B ) is similar to that observed for those GeneChips to which RNA known to be degraded was hybridized (ND-U and TD-U, Figure 1A ; NB-F and TB-F, Figure 1B ). Based on these plots, all chips would be considered to have equivalent RNA quality, demonstrating the ineffectiveness of this method for assessing RNA integrity. For the ovarian samples, the same linear trend is observed for samples processed both with and without the RNeasy cleanup step ( Figure 1A ). Unfortunately, an intact sample may not be fully extended, and since many probe sets interrogate the same transcript in different regions, the variability between specific atn probes in terms of the distance from the 3 end is high, leading to plots which may be strikingly linear even though all external measures of degradation reveal that the RNA was intact. Thus, the RNA digestion plots are also difficult to interpret. Therefore, an objective method of assessing RNA quality that relies on a statistical model is desirable.
MODEL DEVELOPMENT FOR ASSESSING QUALITY
To estimate the 3 to 5 ratio and to provide an estimate of its variance for an individual GeneChip so that confidence intervals or test of hypothesis could be provided, this research proposes the use of pixel-level intensities stored in the resulting *.DAT files with estimation made using mixed-effects models. Note that the raw data for all high-density microarrays are an image file, which are subsequently translated into pixel-level intensities after probe cell addressing. Thus, pixel intensities form the primary data elements that are subsequently evaluated in microarray studies.
As noted, the assessment of RNA quality will become increasingly more important as both the technology for hybridizing archived tissue specimens and the use of laser-capture microdissection for selecting cell populations for RNA extraction increases, since such methods increase the probability of sample degradation. Existing methods for assessing the quality of RNA hybridized to a GeneChip suffer from subjectivity and lack of estimates of variability. Here we propose a method for assessing RNA quality for a hybridized array that overcomes these obstacles that includes estimates of uncertainty.
Selection of features for the model
It has been suggested (Li and Wong, 2001a ) that the high variability observed when using the average difference method for probe set expression summaries may be due to MM probes actually measuring signal for another gene or expressed sequence tag (i.e. cross-hybridization). Similar to RMA which uses only the PM probes in calculating probe set expression summaries, the proposed model was restricted to PM probes.
The Affymetrix HG-U133A and HG-Focus GeneChips include control probe sets for three human genes (GAPDH, β-actin, and ISGF) and two ribosomal RNAs (18S and 28S). Since rRNAs are large, tightly coiled molecules that do not contain polyadenylated 3 ends, hence, the modified oligo(dT) primer used during the reverse transcription step will not bind to these RNA species, and no cDNA product will be generated. Alternatively, partial or total degradation of the total RNA sample could lead to exposure of polyadenylated sequences within the rRNA primary structure, leading to cDNA synthesis and further cRNA products. Thus, the detection call for the rRNA probe sets are useful as a quality assessment of RNA purity. That is, the detection call for 18S and 28S should be 'Absent,' thus indicating high sample integrity. Therefore, they are not useful in estimating the 3 to 5 ratio and were not considered for the model. Further, since the analyst cannot control the design of these commercially manufactured GeneChips, sequence data were used to identify the probes reliably designed to detect these transcripts. Specifically, sequence-verified probes (Mecham et al., 2004) were identified for the HG-U133A GeneChip. Probes that interrogate only the gene of interest (GAPDH, β-actin, and ISGF) were retained. This eliminated three β-actin probes from the 5 probe set (i.e. AFFX-HSAC07/X00351 5 at7, at10, and at11).
Model for assessing RNA quality
There is an inherent nesting structure to Affymetrix GeneChip data, where pixels are nested within probes, probes are nested within probe sets, and a probe set is intended to interrogate a specific region of a transcript. For the proposed method of assessing RNA degradation, the 3 and 5 end probe sets for the three human control genes were retained for analysis (Table 2 ). Since the 3 and 5 ends of a transcript are measured simultaneously, the resulting intensities may be correlated. The internal control genes with probe sets at both the 3 and 5 ends of the transcript present on the GeneChip are a sample from the population of possible transcripts. Although there may be gene-to-gene correlation, for this quality assessment, different genes are assumed independent. Although PM probes represented on an Affymetrix GeneChip were selected based on factors such as probe uniqueness and hybridization characteristics, PM probes are essentially a subsample within the transcript of interest and there is no interest in their specific parameter estimates, and therefore they are treated as random effects in the model. In other words, the PM probes are assumed to be individual experimental units drawn at random from a population of possible 25-mer sequences within a transcript.
To allow for the complex nesting structure and correlations among 3 and 5 measures, RNA degradation was modeled by a mixed-effects analysis of variance (Pinheiro and Bates, 2000) . The least-square means from this model are proposed to estimate the 3 to 5 ratio for the retained probe sets. The covariance structure under this model is such that probe sets interrogating the same transcript (gene) are allowed to be correlated, and the relationship between the probes within a gene can be flexibly modeled. In addition, to further account for hybridization characteristics of the probes, the log 2 of the percent GC content of the probe was included as a fixed effect. As an alternative to the percent GC content, models in which the more recently developed method proposed by Wu et al. (2004) for adjusting for probe-affinity effect was considered were also included. Specifically, instead of estimating the PM probe intensities for the specific probes on the GeneChip, a group-level mean and its variance that appropriately incorporates the within-group correlation are estimated. Since pixel-level intensities share the same level of a classification factor, the mixed-effects models is
where y i jklm represents the log 2 signal intensity for the ith pixel (i = 1, 2, . . . , P), jth end of the transcript ( j = 1, 2), kth gene (k = 1, 2, 3), lth probe set (l = 1, 2, . . . , 6) and mth probe (m = 1, 2, . .
. , M).
The terms in the model are described as follows:
µ represents the overall mean; α j represents the fixed effect associated with the jth end of the transcript; γ l(k) represents the effect associated with the lth probe set nested within the kth gene; δ m(kl) represents the random effect of the mth PM probe nested within the lth probe set nested within the kth gene; x klm represents the log 2 transformed percent GC content for the mth probe; θ represents the regression coefficient associated with the log 2 transformed percent GC content (or probe-affinity effect); and ε i( jklm) represents the error for the ith pixel and are assumed to be ∼N (0, σ 2 ), and ε i( jklm) and ε i( j klm) are correlated.
The nested effects, γ l(k) and δ m(kl) , are treated as random effects and assumed to be normally distributed and independent of each other and of ε i( jklm) . Here, the pixel-level intensities, instead of the probe-level data, are modeled to allow estimation of probe-level covariances in the model. Further, the Affymetrix expression summary algorithm estimates probe-level intensity as the 75th percentile of the interior pixel intensities. Examinations of the distributions of the interior pixel intensities have demonstrated that such distributions are generally skewed to the left. Since estimating central tendency in skewed distributions is an ill-defined problem, use of pixel-level data allows for the log 2 transformed interior pixel intensities to induce symmetry. The random-effects terms thus determine the structure of the variance-covariance matrix G of the random effects. In this model, G is a block diagonal matrix with each block corresponding to a gene, with different genes (i.e. transcripts) assumed to be independent. Thus, the variance structure of the response is V = ZGZ + R.
Two different group covariance structures for G were examined: compound symmetry and first-order autoregressive [AR(1)]. These two covariance structures were selected due to their perceived appropriateness in modeling chips hybridized using various levels of quality RNA. When fitting the model using a compound symmetric covariance structure, we assumed that all probes within a transcript (i.e. across a probe set and within the same gene) are related by a constant correlation factor. The variance-covariance structure is such that the k genes are independent, but covariance of probes and probe sets within the same gene is allowed. For the AR(1) covariance models, the rank order of the probe interrogation position based on the distance from the 5 end was used as the distance (see Supplementary Material for further details). For high-quality RNA, the intensities for 3 and 5 probes for the same transcript (gene) would likely be highly correlated, since the anticipated 3 to 5 ratio is 1. However, we also considered the possibility that for poor-quality RNA, the intensities for the 3 and 5 probes may be uncorrelated. Therefore, alternative models for which the covariance structure assumed independence between probe sets (rather than independence among genes) was also explored (see Supplementary Material for further details and results).
For each GeneChip, since the number of variance parameters estimated was always three, the most appropriate covariance structure was selected as the model with the smallest −2 Residual log likelihood (−2RLL). Once the appropriate covariance structure was determined, the null hypothesis that the 3 to 5 ratio is 1 (or alternatively, that the log difference is 0) was tested against the alternative hypothesis that the ratio is not equal to 1. The general Satterthwaite approximation for the denominator degrees of freedom was used for the estimated variance-covariance matrix for the model parameter estimates. Since a log 2 transformation of the signal intensities was applied to meet model assumptions (Gaussian), the resulting 95% confidence intervals were constructed and then reported using the original scale by retransforming the estimates using antilogs.
Affymetrix's Files Software Developer Kit and additional R code were used to extract the pixel-level data from the *.DAT files included in this degradation study. The mixed-effects models were fit using the PROC MIXED procedure in The SAS System using restricted maximum likelihood.
RESULTS
Selection of covariance structure
Residual maximum likelihood was used for estimation, which explicitly takes into consideration the loss of the degrees of freedom due to the estimation of fixed effects. Preliminary models were fit to each GeneChip to determine the most appropriate covariance structure. For each chip, since the number of parameters are the same, the −2RLL for each fitted model was examined and compared to select the most appropriate covariance structure. For 14 of the 19 GeneChips, the optimal covariance structure was compound symmetry treating genes as independent. For 3 of the 19, the optimal covariance structure was compound symmetry treating probe set as independent, with differences in the −2RLL of only 0.6, 0.2, and 0.6 comparing the gene versus probe set variance-covariance models. Therefore, the estimates of the 3 to 5 ratios and their associated confidence intervals were reported for the compound symmetric variance-covariance structure for all GeneChips.
Interpretation of final models
The estimated 3 to 5 ratios and associated 95% confidence intervals when gene is the blocking factor are reported in Tables 3(A) and 4(A) for the ovarian and renal cell carcinoma samples, respectively, when log 2 percent GC content was included as a fixed effect. For the ovarian samples, the 95% confidence intervals for all GeneChips hybridized with RNA processed without the RNeasy cleanup step did not include one, suggesting poor RNA quality, as appropriate. For the ovarian samples for which the RNeasy cleanup procedure was used, all 95% confidence interval appropriately included one, suggesting adequate sample quality. Similar results were observed when the fixed effect for 'log 2 percent GC content' was replaced by probe-affinity effect (Table 3B) for the ovarian samples.
For the normal and tumor renal cell samples processed when no degradation was present, the 95% confidence intervals included one for all but TA-F1, as appropriate (Table 4A) . Although the confidence interval for the TA-F1 GeneChip excluded one, the lower limit was 1.06 with a p-value of 0.041. For the degraded samples, the 95% confidence intervals for all GeneChips did not include one, suggesting poor RNA quality, again as desired (Table 4A) . However, all the confidence intervals estimated from the models including probe-affinity effect rather than log 2 percent GC content for the degraded renal cell samples all included one, inappropriately indicating good quality (Table 4B ).
Implications for statistical analyses
The rejection of the null hypothesis that the 3 :5 ratio (i.e. the conclusion that the RNA hybridized to the GeneChip is of poor quality) forces the analyst to decide on how to treat the GeneChip in the context of the entire experiment. Due to the high cost of microarrays, investigators may not be willing to eliminate entire samples (GeneChips) from their experiment. Since rejection of this hypothesis indicates a problem of cRNA synthesis, it is possible that probe sets at the 3 end are still usable. That is, for the ovarian samples the median length of the cDNA and cRNA fragments were known (Dumur et al., 2004) to be 300 and 700 bp, respectively, for the samples processed without the RNeasy cleanup step. Therefore, rather than eliminating poor-quality GeneChips from the analysis, the data set may instead be filtered by retaining probe sets close in proximity to the 3 end of the transcript it interrogates. That is, when poor-quality chips are included in a data set, analyses may be appropriately conducted by first restricting the data set to those probe sets in the 3 region of the transcript. This method of filtering is analogous to the manufacturing design of the X3P chip which has an extreme 3 bias among probe sets interrogated (Affymetrix, 2004) . Using the length information available from the paired experiments in the ovarian data set, we restricted the data set to include only sequence-verified probe sets for which all probes were within 500 bp of the 3 end of the transcript (n = 1287). We also restricted the data sets to those sequence-verified probe sets within 500 bp of the 5 end (n = 268). Sequence-verified probe sets required that all probes within the probe set be sequence-verified against the same RefSeqID, and unique for that RefSeqID. All paired comparisons revealed higher correlation among the probe sets on the 3 end in comparison to those on the 5 end (e.g. Figures 2 and 3 ) regardless of the expression summary method (MAS, RMA, and GC-RMA).
In addition, the 3 and 5 end probe sets were classified as 'Present'/'Absent' by the Affymetrix Detection Call algorithm and the respective proportions were compared (Table 5 ). For ovarian samples processed using the RNeasy cleanup step (good), the same relative proportion of probe sets were declared absent for the 3 and 5 ends. However, for ovarian samples processed without the RNeasy cleanup step (inhibited), there was a noted increase in the percent of probe sets declared absent on the 5 compared to the 3 end. This provides further evidence that when poor-quality hybridizations are present in a data set, a biological filtering rule such as restricting the data set to the most 3 probe sets may be appropriate. Fig. 2 . Scatterplot of RMA expression summaries from ovarian sample 2 where the RNeasy cleanup step was performed (x-axis) versus from ovarian sample 2 where the RNeasy cleanup step was not performed (y-axis) for those sequence-verified probe sets on the 3 end of the transcript. 
DISCUSSION
The assessment of RNA quality will become increasingly more important as both the technology for hybridizing archived tissue specimens and the use of laser-capture microdissection for selecting cell populations for RNA extraction increase. Reliance upon probe set expression summaries for assessment of the 3 to 5 ratio lead to irresolvable discrepancies due to their inability to provide uncertainty measures in the absence of replicate probe sets on the GeneChip. Therefore, when using probe set expression summaries one can only assess sample quality by comparing the 3 to 5 ratio to an arbitrarily selected threshold. This often leads to different conclusions when internal control genes are examined using univariate methods. The RNA digestion plots, an alternative, are somewhat subjective in their interpretation of RNA quality as all samples could exhibit the same linear trend regardless of the extent of RNA degradation present.
The proposed use of pixel-level data provides a framework in which the 3 to 5 ratio can be estimated and a confidence interval and test of hypothesis can be conducted. A biostatistical modeling method, namely mixed-effects models, was suggested to achieve this. Two different variance-covariance structures were examined, compound symmetric and AR(1). For the AR(1) model, the ordered position from the 5 end of the transcript was used as the distance measure. As a result, only 2 of the 19 GeneChips exhibited a smaller −2RLL for the AR(1) models. We noted that when hybridizing RNA, whereby the lengths of the fragments are usually 3000 bp pairs in length when RNA is of good quality and 700 bp in length when RNA is degraded or not fully extended, has implications for perhaps why the AR(1) models were not useful. In considering spatial relations between the probes, some other distance metric is likely more appropriate.
For illustration purposes, the proposed model was restricted to the three Affymetrix identified 'housekeeping' genes as there seems to be a general agreement in the field that these genes are expressed at measurable levels (i.e. above the limit of detection) in most tissues. Additional genes could be included to improve the properties of the estimate and the confidence intervals. Research is underway to explore the feasibility of using additional genes in the assessment of RNA quality. This research will include the development of an agreeable definition of a 3 and 5 probe set. Further, in exploring the utility of incorporating additional genes, consideration of differential degradation of genes, which may further influence properties of the estimates and the confidence intervals, will be considered.
Further extensions of mixed-effects models applied to *.CEL-level data may also be appropriate. In addition, this research has provided guidance regarding how to proceed if samples are determined to be of poor quality. That is, when poor-quality hybridizations are present in a data set, a biological filtering rule such as restricting the data set to the most 3 probe sets is appropriate. Therefore, collaboration with biological investigators in determining the most appropriate means for selecting probe sets is essential.
